查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856589

强迫症治疗市场按药物类别、通路、药物类型、给药途径、最终用户和患者年龄组划分－2025-2032年全球预测

Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route Of Administration, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，强迫症药物市场将成长至 19.1738 亿美元，复合年增长率为 8.89%。

关键市场统计数据
基准年 2024 9.6971亿美元
预计年份：2025年 1,054,510,000 美元
预测年份 2032 1,917,380,000 美元
复合年增长率 (%) 8.89%

一本简明扼要的强迫症药物治疗临床和商业性指南，将治疗细节与市场策略要务结合。

强迫症药物治疗领域亟需为临床治疗、产品研发及市场进入等相关相关人员提供清晰简洁的指导。本执行摘要首先聚焦于治疗背景，强调强迫症持续存在的临床复杂性、患者特征的异质性，以及药物治疗与认知行为治疗结合的重要作用。透过介绍实证治疗路径和现有药物类别的多样性，引言部分为深入分析市场动态、监管影响和供应链考量奠定了基础。

引言部分从临床框架出发，探讨了商业性影响，并强调了整合策略思维的必要性，这种思维方式应充分考虑药物类别、分销管道和患者群体的多样性。后续章节阐述了当前的行业趋势、政策变化和市场细分讯息，旨在为高层决策提供依据。这种背景知识有助于读者理解临床实际情况如何转化为商业性槓桿，使他们能够基于数据做出关于产品组合优先事项、患者准入策略和伙伴关係机会的选择。

详细阐述了科学、监管和商业性力量的融合如何塑造强迫症药物的研发路径和上市策略。

强迫症的治疗体係正因不断发展的临床证据、监管调整以及药物研发和递送技术的进步而改变。精准精神病学的最新进展和强迫症亚型表型的精细化，提高了靶点识别的准确性，并重新激发了人们对现有抗忧郁症和新型作用机制的兴趣。同时，监管机构正透过明确适应性试验设计路径，并为存在高度未满足需求的适应症提供快速审批流程，来调整研发时间表和投资策略。

在商业层面，数位疗法和远端保健的整合正在再形成患者就医旅程中的各个环节，改变处方行为，并提升真实世界证据和上市后药物安全检测的重要性。供应链优化、策略性生产伙伴关係以及对可负担性和支付方价值框架的日益关注，都成为重新定义市场准入和规模的新槓桿。总而言之，这些因素正迫使企业重新评估其研发组合，寻求差异化的製剂和给药途径，并采用更具协作性的商业化模式，以使临床获益与支付方和医疗服务提供者不断变化的期望相契合。

对 2025 年美国关税如何改变 OCD 製药价值链的供应链、采购决策和价格谈判进行全面分析。

美国关税将于2025年实施，其累积影响正波及强迫症药物价值链的多个环节，迫使相关人员重新评估供应韧性、成本结构和筹资策略。关税带来的投入成本压力尤其影响原料药和某些特殊辅料，迫使製造商评估替代供应商和生产地区，以便在确保产品品质的同时保护净利率。同时，整个产业正朝着双重采购和增加库存缓衝的方向发展，以应对未来贸易政策的波动。

支付者、采购团队和医院处方医生正在透过加强价格谈判和探索合约前置作业时间。关税也凸显了透明成本模型和情境规划的重要性，促使企业将贸易政策风险纳入供应链决策，并寻求能够吸收或抵销关税影响、同时保障病患用药的策略联盟。

透过整合策略性细分，将药物类别、管道、剂型和患者群体与不同的商业性和临床挑战进行配对。

透过细緻的市场细分，我们可以发现影响强迫症药物需求、使用和竞争压力的差异化商业动态。依药物类别划分，主要的抗忧郁症类别－包括单胺氧化酵素抑制剂（MAOI）、 正肾上腺素再回收抑制剂（SNRI）、选择性血清素再回收抑制剂（ SSRI）和三环抗忧郁药物（ TCAs）－各自展现出不同的疗效和耐受性。 MAOI包括苯乙肼和反苯环丙胺；SNRIDesvenlafaxine、FluoxetineDuloxetine和文拉法辛；SSRI包括西酞普兰、氟西汀、氟伏沙明、帕罗西汀和舍曲林；TCAs包括阿米替林、氯米帕明和丙咪嗪。这些治疗上的细微差别会影响处方模式、药物转换行为和长期用药依从性。

分销管道动态涵盖医院药房、线上药房和零售药房，每种管道满足不同的患者用药需求和报销途径，从而影响产品的商业化和支援方式。依药物类型划分品牌药和学名药市场，会影响定价策略、生命週期管理方法和商业化投资。给药途径（例如口服与注射）会影响製剂优先顺序、依从性支持需求和临床给药环境。终端使用者（例如诊所、医院和家庭）的划分反映了采购週期、医疗服务模式和病患教育需求的差异。最后，由于安全考量、给药模式和监管文件的不同，将患者群体划分为成人和儿童群体，需要采取不同的临床应用和市场渗透策略。

提供实用的区域信息，解释美洲、欧洲、中东和非洲以及亚太地区的市场动态如何需要不同的商业化和市场准入策略。

强迫症药物的研发、报销和交付方式在不同地区差异显着，需要製定相应的策略。在美洲，准入框架、支付方的多样性以及蓬勃发展的民营市场共同塑造了药物商业化策略，并优先考虑证据的生成，以支持药物纳入医保目录和获得医保报销。该地区强调以结果为导向的合约和真实世界证据，以证明药物在各种医疗服务模式下的价值。

欧洲、中东和非洲的监管方式和报销环境呈现出多元化的格局，在集中监管路径、国家卫生技术评估要求以及新兴市场限制等方面存在显着差异。亚太地区正在快速推广数位医疗模式，本土生产的学名药和生物相似药的作用日益增强。在所有地区，不断发展的患者权益倡导、远端医疗的普及以及对本地化生产的考量，都将导致市场准入和规模的差异化。

竞争考察和企业行动着重于创新、生命週期管理和伙伴关係策略，这些因素共同塑造了强迫症治疗产品组合。

强迫症治疗领域的竞争和企业活动体现了创新投资、生命週期管理以及旨在解决准入和差异化问题的伙伴关係的融合。各公司正加大对后期临床项目的投入，力求在疗效和耐受性方面超越现有标准疗法，同时透过改进製剂、缓释性和组合药物疗法来优化产品组合。随着各公司寻求互补的非药物解决方案以改善整体疗效，与学术中心和数位医疗供应商的研究合作也日益普遍。

同时，学名药的上市和专利到期药物的出现给定价和报销带来了压力，迫使原厂药企业透过疗效数据和配套服务来强调品牌价值。策略许可、共同促销和本地化生产协议正被用于促进分销和降低供应风险。投资人对研发效率的严格审查促使企业更加重视那些具有明确临床差异化和监管奖励的项目。整体而言，企业策略正趋向于在创新、成本控制和伙伴关係之间取得平衡，以保持竞争力并满足支付方和患者的期望。

为企业主管提供切实可行的建议，以增强强迫症药物的供应韧性、证据产生和价值主导商业化。

致力于巩固自身在强迫症治疗领域地位的产业领导者应优先采取一系列切实有效、影响深远的倡议，以增强自身韧性并实现商业性差异化。首先，透过在临床试验设计早期阶段纳入健康经济学和结果研究，使临床开发方案与支付方的证据要求相符，将缩短获得处方笺的路径。同时，透过地理多元化和策略性生产协议来强化供应链，将降低贸易政策衝击带来的风险，并确保供应的持续性。

领导者也应透过投资数位化和病患支援服务来强化产品价值提案，从而提高病患依从性和实际疗效。与行为健康服务提供者和远端医疗平台合作，可以扩大服务覆盖范围，惠及服务不足的患者群体，并创建整合式医疗解决方案。最后，采用动态定价和合约框架，以反映在不同医疗环境中提供的价值，并积极监控监管和报销政策的变化，灵活应对。透过采取这些协调一致的倡议，企业既能提供具有临床意义的创新，又能保障医疗服务的可近性和商业性可行性。

我们采用透明的多方法研究途径，将主要相关人员调查与系统性的二手证据相结合，从而提供可靠、可重复的策略见解。

本执行分析所依据的研究结合了第一手资料和第二手资料，以确保提供可靠且多角度验证的洞见。第一手资料包括对临床医生、负责人、采购负责人和生产专家进行结构化访谈，以了解医疗机构的实践做法、处方行为和获取途径的限制。第二手资料包括对同行评审的临床文献、监管指导文件、临床试验註册库和公开的安全报告进行系统性回顾，以检验治疗趋势和证据缺口。

分析方法酌情结合了定性综合和定量趋势分析，包括对监管申请、专利状态和供应链事件历史进行时间序列分析。专家咨询和基于情境的敏感性检验被用于交叉检验有关供应风险和政策影响的假设。整个过程始终遵循伦理原则并专注于资料来源，并着重于方法论的透明度和可重复性，以使相关人员能够充满信心地做出决策。

执行综合分析强调，需要整合临床差异化、供应弹性以及以患者为中心的策略，才能使强迫症药物持续疗效。

总之，当代强迫症治疗领域面临临床、监管和商业方面的多重压力与机会。临床认识的进步和辅助性数位化干预措施的出现，为改善病患疗效铺平了道路；而贸易政策的转变和学名药竞争的加剧，正在重塑成本和供应格局。因此，决策者必须将实证医学、供应链韧性和以病人为中心的支援服务整合到一个连贯的策略中，该策略既要反映当地市场实际情况，又要满足支付方的期望。

透过优先考虑差异化的临床价值、增强生产和采购的灵活性，以及​​利用伙伴关係关係拓展医疗服务范围，相关人员可以在应对政策变化和竞争压力的同时，改善病患就医途径。这些措施的综合效果将决定哪些机构能够将科学进步可持续地转化为广泛的临床影响和持久的商业性成功。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 迷幻药辅助性治疗（如裸盖菇素）在治疗难治性强迫症的临床试验中兴起
  • 越来越多地使用数位疗法和远距精神病学平台进行远距强迫症症状管理
  • 利用基因生物标记预测强迫症药物疗效的精准医疗策略的进展
  • 麸胺酸调节剂作为一种新型作用机制，在强迫症药物研发中越来越受到重视。
  • 扩大真实世界临床试验和病患报告结果数据，以影响强迫症药物的报销决策
  • 针对严重强迫症治疗候选药物的监管进展，可望获得快速通道资格和孤儿药认定
  • 价格竞争压力将推动现有 SSRI 类药物的学名药和生物相似药的研发。
  • 增加强迫症联合治疗试验的投资，将药物治疗与认知行为介入结合。
  • 将亚太地区和拉丁美洲等新兴市场拓展为强迫症药物的新增长途径
  • 针对儿童和青少年强迫症治疗的研究将加速儿科专用製剂的开发和核准。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的强迫症治疗市场

  • MAOI
    • 苯乙肼
    • 反式环丙胺
  • SNRI
    • Desvenlafaxine
    • Duloxetine
    • 文拉法辛
  • SSRI
    • 西酞普兰
    • Fluoxetine
    • 氟伏沙明
    • 帕罗西汀
    • 舍曲林
  • TCAs
    • 阿米替林
    • 氯米帕明
    • 丙咪嗪

9. 强迫症治疗药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十章 强迫症治疗药物市场（依药物类型划分）

  • 品牌
  • 非专利的

第十一章 强迫症治疗市场（依给药途径划分）

  • 口服
  • 肠外

第十二章 强迫症治疗药物市场（依最终使用者划分）

  • 诊所
  • 医院
  • 家

第十三章 依患者年龄层分類的强迫症治疗药物市场

  • 成人版
  • 孩子们

第十四章 各地区强迫症治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 强迫症治疗药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国强迫症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Johnson & Johnson
Product Code: MRR-742BD51822E2

The Obsessive-Compulsive Disorder Drugs Market is projected to grow by USD 1,917.38 million at a CAGR of 8.89% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 969.71 million
Estimated Year [2025] USD 1,054.51 million
Forecast Year [2032] USD 1,917.38 million
CAGR (%) 8.89%

Concise clinical and commercial orientation to obsessive-compulsive disorder pharmacotherapy that aligns therapeutic nuance with strategic market imperatives

The landscape of pharmacological interventions for obsessive-compulsive disorder demands a clear, concise orientation for stakeholders operating at the intersection of clinical care, product development, and market access. This executive summary opens with a focused introduction to the therapeutic context, highlighting the enduring clinical complexity of OCD, the heterogeneity of patient presentations, and the critical role that pharmacotherapy plays alongside cognitive and behavioral approaches. By emphasizing evidence-based treatment pathways and the diversity of available drug classes, the introduction sets the stage for deeper analysis of market dynamics, regulatory influences, and supply chain considerations.

Transitioning from clinical framing to commercial implications, the introduction underscores the need for integrated strategic thinking that accounts for variations in drug classes, distribution channels, and patient demographics. It clarifies that the subsequent sections synthesize current industry trends, policy shifts, and segmentation intelligence to inform senior-level decisions. This contextual foundation ensures readers appreciate how clinical realities map onto commercial levers, enabling data-driven choices about portfolio prioritization, patient access strategies, and partnership opportunities.

Detailed account of converging scientific, regulatory, and commercial forces reshaping development pathways and market access strategies for OCD pharmacotherapies

The therapeutic ecosystem for obsessive-compulsive disorder is undergoing transformative shifts driven by evolving clinical evidence, regulatory recalibrations, and technological advances in drug development and delivery. Recent progress in precision psychiatry and more refined phenotyping of OCD subtypes has sharpened target identification and reinvigorated interest in both established antidepressant classes and novel mechanisms of action. Concurrently, regulators are clarifying pathways for adaptive trial designs and expedited review for high-unmet-need indications, which is altering development timelines and investment calculus.

On the commercial front, digital therapeutics and telehealth integration are reshaping patient journey touchpoints and altering prescribing behavior, increasing the importance of real-world evidence and post-market pharmacovigilance. Supply chain optimization, strategic manufacturing partnerships, and an intensifying focus on affordability and payer value frameworks represent additional levers redefining market entry and scale. Collectively, these forces are prompting companies to re-evaluate R&D portfolios, pursue differentiated formulations and delivery routes, and adopt more collaborative commercialization models that align clinical benefit with payers' and providers' evolving expectations.

Comprehensive analysis of how the 2025 United States tariff measures are reshaping supply chains, sourcing decisions, and pricing negotiations across the OCD drug value chain

The cumulative impact of the United States tariffs introduced in 2025 is manifesting across multiple nodes of the obsessive-compulsive disorder drug value chain, forcing stakeholders to reassess supply resilience, cost structures, and sourcing strategies. Tariff-induced input cost pressures have particularly affected active pharmaceutical ingredients and certain specialized excipients, prompting manufacturers to evaluate alternative suppliers and production geographies to preserve margins while maintaining product quality. These adjustments have occurred alongside a broader industry trend toward dual sourcing and enhanced inventory buffering to mitigate future trade policy volatility.

Payers, procurement teams, and hospital formularies are responding by intensifying price negotiations and seeking contracting mechanisms that de-risk exposure to tariff-driven cost variability. Regulators and trade bodies have engaged in targeted dialogue to ensure continuity of critical medicines, and some firms have accelerated onshoring and regional manufacturing investments to circumvent duties and shorten lead times. The tariffs have also elevated the importance of transparent cost modeling and scenario planning, encouraging companies to incorporate trade policy risk into supply chain decisions and to explore strategic alliances that can absorb or offset tariff impacts while preserving patient access.

Strategic segmentation synthesis that maps drug classes, channels, formulations, and patient cohorts to differentiated commercial and clinical imperatives

A nuanced segmentation lens reveals the differentiated commercial dynamics that govern OCD pharmacotherapy demand, uptake, and competitive pressures. When examining drug class, major antidepressant categories including monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants each present distinct efficacy and tolerability profiles, with MAOIs further represented by phenelzine and tranylcypromine, SNRIs by desvenlafaxine, duloxetine, and venlafaxine, SSRIs by citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, and TCAs by amitriptyline, clomipramine, and imipramine; these therapeutic nuances influence prescribing patterns, switching behavior, and long-term adherence.

Distribution channel dynamics encompass hospital pharmacies, online pharmacies, and retail pharmacies, each serving different patient access needs and reimbursement pathways and shaping how products are merchandised and supported. Drug type segmentation across brand and generic markets drives pricing strategies, lifecycle management approaches, and commercialization investments. Route of administration-oral versus parenteral-affects formulation priorities, adherence support requirements, and clinical settings for administration. End-user distinctions among clinics, hospitals, and households reflect divergence in procurement cycles, care delivery models, and patient education imperatives. Finally, patient age group segmentation into adult and pediatric cohorts requires distinct safety considerations, dosing paradigms, and regulatory dossiers, making a tailored approach essential for clinical adoption and market penetration.

Actionable regional intelligence explaining how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics demand tailored commercialization and access strategies

Regional nuances materially affect how OCD pharmacotherapies are developed, reimbursed, and delivered, demanding geographically customized strategies. In the Americas, access frameworks, payer heterogeneity, and a robust private market shape commercialization tactics and prioritization of evidence generation that supports formulary inclusion and reimbursement. This region emphasizes outcomes-oriented contracting and real-world evidence to demonstrate value within diverse healthcare delivery models.

Europe, the Middle East & Africa present a mosaic of regulatory approaches and reimbursement environments, with pronounced differences between centralized regulatory pathways, national health technology assessment requirements, and emerging market constraints; companies must balance harmonized clinical data packages with localized health economic models. The Asia-Pacific region displays rapid adoption of digital health modalities and an expanding role of domestically manufactured generics and biosimilars, necessitating strategies that account for local manufacturing partnerships, variable payer coverage, and cultural dimensions of mental health care. Across all regions, evolving patient advocacy, telemedicine uptake, and regional manufacturing considerations inform differentiated market entry and scaling choices.

Insightful corporate behavior and competitive positioning analysis highlighting innovation, lifecycle management, and partnership strategies shaping OCD therapeutic portfolios

Competitive and corporate behavior within the obsessive-compulsive disorder drug space reflects a blend of innovation investment, lifecycle management, and partnerships to address access and differentiation. Organizations are increasing investment in late-stage clinical programs that seek improved efficacy or tolerability versus existing standards, while simultaneously optimizing portfolios through formulation improvements and extended-release or combination approaches. Research collaborations with academic centers and digital health vendors are becoming more common as companies pursue complementary nonpharmacologic solutions to enhance overall outcomes.

At the same time, generic entrants and established off-patent molecules exert pressure on pricing and reimbursement, compelling originators to emphasize brand value via outcomes data and support services. Strategic licensing, co-promotion, and regional manufacturing agreements are being used to accelerate distribution and reduce supply risk. Investor scrutiny around R&D productivity has prompted tighter prioritization of programs with clear clinical differentiation or regulatory incentives. Overall, corporate strategies are converging on a balanced mix of innovation, cost discipline, and partnership to sustain competitiveness while addressing payer and patient expectations.

Practical and high-leverage recommendations for executives to strengthen supply resilience, evidence generation, and value-driven commercialization in OCD therapeutics

Industry leaders seeking to strengthen their position in the OCD therapeutic domain should prioritize a set of pragmatic, high-impact actions that enhance resilience and commercial differentiation. First, align clinical development choices with payer evidence requirements by integrating health economics and outcomes research early in trial design to shorten the path to formulary acceptance. Simultaneously, fortify supply chains through regional diversification and strategic manufacturing agreements to reduce exposure to trade policy shocks and ensure continuity of supply.

Leaders should also invest in digital and patient-support services that improve adherence and real-world outcomes, thereby reinforcing product value propositions. Partnerships with behavioral health providers and telemedicine platforms can extend reach into under-served patient segments and create integrated care solutions. Finally, adopt dynamic pricing and contracting frameworks that reflect value delivered across varied care settings, and maintain an active watch on regulatory and reimbursement shifts to respond nimbly. Executing these coordinated moves will better position companies to deliver clinically meaningful innovations while safeguarding access and commercial viability.

Transparent, multi-method research approach integrating primary stakeholder interviews with systematic secondary evidence to deliver reliable, reproducible strategic insights

The research underpinning this executive analysis combines primary and secondary approaches to ensure robust, triangulated insights. Primary engagement included structured interviews with clinicians, payers, procurement officers, and manufacturing experts to capture operational realities, prescribing behavior, and access constraints across care settings. Secondary research entailed systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and publicly available safety reports to validate therapeutic trends and evidence gaps.

Analytical techniques integrated qualitative synthesis with quantitative trend analysis where appropriate, including time-series examination of regulatory filings, patent landscapes, and supply chain event histories. Cross-validation was achieved through subject matter expert consultations and scenario-based sensitivity checks to test assumptions about supply risk and policy impact. Ethical considerations and data provenance were maintained throughout the process, with a clear emphasis on transparency and reproducibility of methods to support confident decision-making by stakeholders.

Executive synthesis emphasizing the imperative to integrate clinical differentiation, supply resilience, and patient-centric strategies to achieve sustainable impact in OCD therapeutics

In conclusion, the contemporary OCD therapeutic environment is characterized by simultaneous pressures and opportunities across clinical, regulatory, and commercial dimensions. Advances in clinical understanding and the emergence of complementary digital interventions are opening pathways for improved patient outcomes, while trade policy shifts and intensified generic competition are reshaping cost and supply dynamics. Decision-makers must therefore integrate evidence generation, supply chain resilience, and patient-centric support services into cohesive strategies that reflect regional market realities and payer expectations.

By prioritizing differentiated clinical value, strengthening manufacturing and sourcing flexibility, and leveraging partnerships to extend care delivery, stakeholders can navigate policy volatility and competitive pressure while improving access for patients. The combined effect of these actions will determine which organizations can sustainably translate scientific progress into broad clinical impact and enduring commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rise of psychedelic-assisted therapies like psilocybin in clinical trials for treatment-resistant OCD
  • 5.2. Increased utilization of digital therapeutics and telepsychiatry platforms for remote OCD symptom management
  • 5.3. Advancements in precision medicine strategies using genetic biomarkers to predict OCD drug response
  • 5.4. Growing focus on glutamate-modulating agents as novel mechanisms of action in OCD treatment pipelines
  • 5.5. Expansion of real-world evidence and patient-reported outcome data influencing OCD drug reimbursement decisions
  • 5.6. Regulatory momentum for fast-track designations and orphan drug status in severe OCD therapeutic candidates
  • 5.7. Competitive pricing pressures driving development of generic and biosimilar alternatives to established SSRIs
  • 5.8. Rising investment in combination therapy trials pairing pharmacologics with cognitive behavioral interventions for OCD
  • 5.9. Emerging market expansion in Asia-Pacific and Latin America as new growth avenues for OCD therapeutics
  • 5.10. Pediatric and adolescent-focused OCD drug research accelerating child-specific formulation development and approval

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class

  • 8.1. MAOIs
    • 8.1.1. Phenelzine
    • 8.1.2. Tranylcypromine
  • 8.2. SNRIs
    • 8.2.1. Desvenlafaxine
    • 8.2.2. Duloxetine
    • 8.2.3. Venlafaxine
  • 8.3. SSRIs
    • 8.3.1. Citalopram
    • 8.3.2. Fluoxetine
    • 8.3.3. Fluvoxamine
    • 8.3.4. Paroxetine
    • 8.3.5. Sertraline
  • 8.4. TCAs
    • 8.4.1. Amitriptyline
    • 8.4.2. Clomipramine
    • 8.4.3. Imipramine

9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type

  • 10.1. Brand
  • 10.2. Generic

11. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Obsessive-Compulsive Disorder Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Households

13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Pediatric

14. Obsessive-Compulsive Disorder Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obsessive-Compulsive Disorder Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obsessive-Compulsive Disorder Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Pfizer Inc.
    • 17.3.2. Eli Lilly and Company
    • 17.3.3. GlaxoSmithKline plc
    • 17.3.4. H. Lundbeck A/S
    • 17.3.5. Teva Pharmaceutical Industries Ltd.
    • 17.3.6. Novartis AG
    • 17.3.7. Sun Pharmaceutical Industries Ltd.
    • 17.3.8. Viatris Inc.
    • 17.3.9. Otsuka Pharmaceutical Co., Ltd.
    • 17.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)

TABLE 28